If this box remains here for more than 30 seconds, click this link to try again.
Industries
Functions
Home » Products & Services » Best Practice Database » Product Launch » Product Launch Excellence
Download FREE Excerpt
11 Info Graphics
11 Data Graphics
50+ Metrics
14 Narratives
Single User: Authorizes use by the person who places the order or for whom the order was placed.
Sitewide: Authorizes use of the report for a geographic site. All people at site can view the report for a year and copies can be printed.
Corporate: Authorizes use for the entire company for a year and copies can be printed. No limitations for usage inside the company.
Buy Now
STUDY OVERVIEW Assessing the success of a pharma product launch is a complex yet critical activity to improve both product and process performance. However, most launch teams around the industry struggle to develop a strong product launch evaluation process and system to drive successful market entry. Best Practices, LLC undertook this benchmarking research to help launch leaders identify and evaluate the performance measures used for successful pharmaceutical product launches. This benchmark study presents benchmarks for informing and shaping evaluations of biopharma launches. In particular, this study examines the launch evaluation process and the timetable for recalibration of launch targets. It includes lessons learned from study participants about launch evaluation. KEY TOPICS
Industries Profiled: Biotech; Pharmaceutical; Health Care; Biopharmaceutical; Clinical Research; Laboratories; Consumer Products; Chemical; Medical Device; Communications; Consulting Companies Profiled: Amgen; Sanofi; Merck; Novartis; Eisai; Genentech; Sunovion; Grünenthal; GlaxoSmithKline ; Novo Nordisk; UCB Pharma; BIOCAD; Sanofi Genzyme; ASC Therapeutics; APR Applied Pharma Research; Prothena; Karyopharm Therapeutics; Alcon; Arvelle Therapeutics; BeiGene; Dendreon; NexGen Healthcare Communications; MEDiSTRAVA; Klosterfrau Healthcare Group; Kala Pharmaceuticals; Inc.; Bioviiix; Nutricia; Scilex Pharmaceuticals; NeuroTau; Medexus Pharmaceuticals; Theravance; Supernus; Viatris
If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.
Top